Clinical Trial Update: A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer [Phase 2]

View source ↗

Summary

Phase II trial update evaluating camrelizumab with long-course chemoradiotherapy as total neoadjuvant therapy for locally advanced rectal cancer (low pMMR/MSS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Locally Advanced Rectal Cancer | Phase 2 | Status: RECRUITING